Oncology Views & Analysis

Views & Analysis

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Oncology

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Digital

Ovarian cancer, Olivia, and the OCC – part one

Following the European Society of Gynaecological Oncology (ESGO) 2022 congress, pharmaphorum spoke with experts from among the Ovarian Cancer Commitment (OCC) founding partners – ESGO, the

Oncology

JP Morgan 2023 - Raj Chopra

On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics.

Oncology

Cancer control in a time of crisis - the pharmaphorum podcas...

During The Economist’s 8th Annual World Cancer Series congress in Brussels November last year, web editor Nicole Raleigh sat down to discuss the event and its themes with

Digital

A few of 2022’s biggest pharma trends – the pharmaphorum pod...

As we close out the year, pharmaphorum's editorial team sat down together for a roundtable discussion of some of the biggest trends they tracked this year in the world of

Oncology

After a slow start for expensive CAR-T therapies, drug devel...

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o

How can digital and AI optimise the delivery of patient supp...

Ovarian cancer, Olivia, and the OCC – part one

JP Morgan 2023 - Raj Chopra

Cancer control in a time of crisis - the pharmaphorum podcas...

A few of 2022’s biggest pharma trends – the pharmaphorum pod...

After a slow start for expensive CAR-T therapies, drug devel...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Views & Analysis

Editor's Picks